Q3 2025 Ascendis Pharma A/S Earnings Call Transcript

Nov 12, 2025 / 09:30 PM GMT

Release Date Price: MXN3678

Transcript

Key Points

Positve

Ascendis Pharma AS (ASND) reported strong global revenue growth for its product, Europath, reaching €143 million in Q3 2025, up from €103 million in Q2.
The company achieved positive operating income and cash flow in Q3, signaling a transformation in its financial profile.
Skytrofa, a once-weekly growth hormone, contributed €50.7 million in Q3 revenue, with a 3% growth in demand.
The company is expanding its market presence, with Europath now available in over 30 countries, including recent launches in Japan and full commercial reimbursement in Germany, Austria, and Spain.
Ascendis Pharma AS (ASND) is progressing towards potential approval of Transcon CMP in the US and EU, with a priority review due date of November 30, 2025.

Negative

The approval rate for Europath is currently at 70%, which the company expects to improve over time, indicating room for growth in payer acceptance.
SG&A expenses rose significantly to €113.4 million in Q3 2025 from €69.8 million in the same period last year, reflecting the impact of global commercial expansion.
Net finance expense for Q3 2025 was €60.9 million, primarily driven by non-cash items, including a non-cash remeasurement loss of financial liabilities.
The company faces foreign currency headwinds, with a €3.6 million impact on Europath revenue and a €1.6 million impact on Skytrofa revenue in Q3.
The market for Transcon CMP is underpenetrated, and the company acknowledges the need to address comorbidities to improve patient uptake.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ASND.OQ - Ascendis Pharma A/S
Q3 2025 Ascendis Pharma A/S Earnings Call
Nov 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
To the third quarter 2025, ascendis Farmer earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question, please press 11. If your question has been answered and you'd like to remove yourself from the queue, press 11 again. We ask that you limit yourself to one question and one follow-up. I would like to turn the call over to Chad Fugi, Vice President of Investor relations at Ascendis Pharma. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.